Bill expands national security screening to biotech deals.

What it does

The bill treats biotechnology as a national security technology. Four agencies must decide which biotech deals get reported or stopped. These agencies are Treasury, Defense, Health and Human Services, and Intelligence. The bill aims to prevent U.S. money and intellectual property from going to Chinese biotech firms. It covers licensing, joint ventures, and equity investments.

Who it affects

Biotech companies, pharmaceutical firms, and clinical research organizations may face new rules. U.S. biotech companies may find it harder to partner with foreign firms. Patients could see delays or higher costs for new drugs.

One thing to notice

The bill gives four agencies broad power to block or report biotech deals. The bill does not set clear limits on that power. The bill does not define strategic dependency risk.

From the analysis of the bill text, linked under Primary records below.

Where it stands

1 cosponsor: 1 Democrats.

• Jun 2, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 2, 2026 — Referred to House Committee on Financial Services · Congress.gov: “Referred to the House Committee on Financial Services”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 groups reported lobbying about this bill. They filed 13 reports from Jun 2026 to Jun 2026.

Those reports show $18,610,000 in lobbying spending. Each report lists about 19 bills. So that money was not all for this bill.

More groups named this bill than 94% of bills with any report.

John Moolenaar, who sponsored the bill, received $565,100 from PACs for the 2026 election.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 in 1 report
• Amgen Inc — $2,440,000 in 1 report
• Biotechnology Innovation Organization — $2,360,000 in 1 report
• Pfizer Inc. — $1,880,000 in 1 report
• Novartis — $1,410,000 in 1 report

Lobbying is legal. These reports show who lobbied about this bill, not what changed.

Words to know

• biotechnology — Science of using living things to make medicines, drugs, and treatments.
• intellectual property — Creations of the mind, like inventions and discoveries a company owns.
• equity investments — Money put into a company in exchange for partial ownership.
• joint ventures — Business partnerships where two or more companies work together.
• lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
• PACs — Groups that collect money and give it to candidates for office.